Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Mazzara

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Vaccine|March 6, 1999
The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulationR M Kalus, J A Kantor, L Gritz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1991
HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cellsR P Johnson, A Trocha, L Yang, et al.
Science (New York, N.Y.)|April 19, 1991
Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytesL Shen, Z W Chen, M D Miller, et al.
The Journal of Experimental Medicine|December 1, 1991
Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificitiesR A Koup, C A Pikora, K Luzuriaga, et al.
AIDS Research and Human Retroviruses|July 1, 1994
High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infectionM D Daniel, G P Mazzara, M A Simon, et al.
Journal of Virology|October 29, 1997
Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine developmentH Cao, P Kanki, J L Sankalé, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1990
Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysisH Yamamoto, M D Miller, D I Watkins, et al.
Annals of Surgical Oncology|April 3, 1998
Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivityC J Kim, J Cormier, M Roden, et al.
AIDS Research and Human Retroviruses|August 1, 1998
Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infectionS E Wilson, S L Pedersen, J C Kunich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1990
Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificityH Yamamoto, M D Miller, H Tsubota, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Vaccine|March 6, 1999
The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulationR M Kalus, J A Kantor, L Gritz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 1, 1991
HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cellsR P Johnson, A Trocha, L Yang, et al.
Science (New York, N.Y.)|April 19, 1991
Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytesL Shen, Z W Chen, M D Miller, et al.
The Journal of Experimental Medicine|December 1, 1991
Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificitiesR A Koup, C A Pikora, K Luzuriaga, et al.
AIDS Research and Human Retroviruses|July 1, 1994
High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infectionM D Daniel, G P Mazzara, M A Simon, et al.
Journal of Virology|October 29, 1997
Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine developmentH Cao, P Kanki, J L Sankalé, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1990
Two distinct lymphocyte populations mediate simian immunodeficiency virus envelope-specific target cell lysisH Yamamoto, M D Miller, D I Watkins, et al.
Annals of Surgical Oncology|April 3, 1998
Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivityC J Kim, J Cormier, M Roden, et al.
AIDS Research and Human Retroviruses|August 1, 1998
Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infectionS E Wilson, S L Pedersen, J C Kunich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1990
Studies of cloned simian immunodeficiency virus-specific T lymphocytes. gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificityH Yamamoto, M D Miller, H Tsubota, et al.
Pageof 3